SCHEMBL6206523

SCHEMBL6206523

CCCCOc1ccc(-c2ccc(S(=O)(=O)C3(C(=O)O)CCOCC3)s2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 16/20 0.53
MMP1 P03956 5/20 0.53
MMP9 P14780 4/20 0.53
ADAM17 P78536 2/20 0.53
MMP2 P08253 5/20 0.45
MMP8 P22894 5/20 0.45
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6206734 0.89 MMP13 (0.70) MMP13MMP1MMP9ADAM17MMP2
SCHEMBL6207339 0.88 MMP13 (0.49) MMP13MMP1MMP9ADAM17MMP2
SCHEMBL6207341 0.84 MMP13 (0.40) MMP13MMP1MMP9ADAM17MMP2
SCHEMBL6205603 0.80 MMP13 (0.49) MMP13MMP1MMP9ADAM17MMP2
SCHEMBL6227180 0.79 MMP9 (0.40) MMP13MMP1MMP9MMP2MMP8
SCHEMBL6207817 0.74 MMP13 (0.48) MMP13MMP1MMP9MMP2CYP1A2
SCHEMBL5908627 0.74 MMP13 (0.59) MMP13MMP1MMP9ADAM17MMP2
SCHEMBL6205985 0.73 CYP2D6 (0.49) MMP13MMP1ALDH1A1LMNACYP1A2
SCHEMBL8334812 0.73 MMP13 (0.61) MMP13MMP1MMP9ADAM17MMP2
SCHEMBL6206170 0.73 L3MBTL1 (0.47) MMP13ALDH1A1LMNACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1565459-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS Pharmacia Corporation (US) 2005-08-24 EP disclosed
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors PHARMACIA CORPORATION 2004-07-22 US disclosed
WO-2004048368-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-06-10 WO disclosed
WO-2004048368-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors MMP3, MMP13, MMP10 MMP13 2/4885MMP1 5/4885MMP9 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.